Saline Enhanced Radiofrequency (SERF) Needle Ablation for Refractory VT
NCT ID: NCT05337241
Last Updated: 2025-08-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
130 participants
INTERVENTIONAL
2025-08-09
2027-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Subjects with recurrent, SMVT refractory to drug therapy and conventional catheter ablation who are not eligible for, or will not likely benefit from repeat endocardial ablation using an approved catheter.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
SERF VT Ablation Early Feasibility Study (EFS)
NCT03628534
Saline-Enhanced Radiofrequency (SERF) Catheter Ablation for the Treatment of Ventricular Tachycardia
NCT02994446
VT Ablation in the iCMR
NCT05543798
Cohort Study - SBRT for VT Radioablation
NCT04162171
Endo-epicardial vs Endocardial-only Catheter Ablation of Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy (EPIC-VT)
NCT05888662
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Subjects will be consented (enrolled) and screened prior to the study ablation procedure. 154 subjects will have a study ablation procedure with the investigational device. Follow-up will occur at 7 days, 30 days, 3 months and 6 months.
The single arm design of the proposed study reflects the nature of the study population. The Thermedical Ablation System was designated as a Breakthrough technology in part because no currently approved device specifically treats this refractory patient population.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single arm treatment
All subjects meeting inclusion/exclusion criteria and successfully consented will be treated with the study device.
Saline Enhanced Radiofrequency (SERF) Ablation
The Durablate intramural needle catheter delivers heated saline to target tissue in the left ventricle to target mid-myocardial and epicardial VT substrates
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Saline Enhanced Radiofrequency (SERF) Ablation
The Durablate intramural needle catheter delivers heated saline to target tissue in the left ventricle to target mid-myocardial and epicardial VT substrates
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subject has recurrent symptomatic sustained (\> 30 seconds) monomorphic ventricular tachycardia (MMVT) within 180 days prior to planned study ablation that meets the following criteria:
1. At least 3 episodes of the MMVT have been treated with ATP and/or shock, OR at least 2 episodes were treated with shock AND
2. Documentation of the presumed recurrent MMVT was treated with prior catheter ablation AND
3. Occurred despite treatment with at least one Class III antiarrhythmic after last ablation or treatment with a Class III antiarrhythmic is not tolerated or is contraindicated AND
4. VT has recurred despite VT ablation at one of the investigational centers UORU the investigator documents the reason that the subject is unlikely to benefit from a repeat ablation using a conventional, approved catheter.
3. Subject is at least 18 years old
4. Subject has an implantable cardioverter-defibrillator (ICD) with a full 6-month (prior to planned study ablation) ICD interrogation history documenting incidences of VT
5. Subject is able to provide informed consent
Exclusion Criteria
2. Suspected area of ablation of target clinical VT includes aortic root, aortic cusp or any area outside left ventricle except the ventricular septum
3. Subject with a prior ablation within 4 weeks of planned study ablation
4. Subject's VT is not amenable to treatment with the study device at the time of mapping for the study ablation
5. Only PVCs are induced during mapping for the study ablation
6. No clinical VT induced during mapping for the study ablation
7. Planned use of a non-study ablation catheter
8. Subject has an LVEF \< 20% reported on pre-ablation imaging (CT, MRI or echocardiogram within 48 hours of the study procedure)
9. Subject with evidence of any right- or left-sided (including left atrium, left atrial appendage and left ventricle) intracardiac thrombus OR pericardial effusion (except chronic trivial) reported on required pre-ablation imaging (CT, MRI, or echocardiography) or seen on required procedural intracardiac echocardiography (ICE) prior to study ablation catheter insertion.
10. Subjects with atrial fibrillation/flutter (paroxysmal, persistent, or permanent) without uninterrupted anticoagulation for at least 3 weeks immediately prior to the date of ablation procedure. (Interruption of anticoagulation in the day(s) just prior to ablation will be left to physician decision based upon subject's risk of stroke, anticoagulation agent, renal status, and bleed/embolic risk status with recommendation to consider bridging for high-risk subjects.
11. Subjects with NYHA Class IV heart failure
12. Renal dysfunction with eGFR \<30 ml/min/1.73mP2
13. Subject with known coagulopathy or other condition likely to increase risk of periprocedural bleeding
14. Subject with known coagulopathy or other condition likely to increase risk of a thrombotic event
15. Subject with a mechanical aortic valve, mechanical mitral valve, or MitraClip
16. Subject with flail mitral leaflet or severe aortic stenosis
17. Subject with LAA occlusion device
18. Subject with a congenital heart defect except patent foramen ovale (PFO)
19. Subject with suspected life expectancy of less than 1 year
20. Subject with myocardial infarction (MI) or unstable angina (UA) within previous 90 days
21. Subject with cardiac surgery or percutaneous coronary intervention (PCI) within previous 90 days
22. Subject with known untreated significant ischemic coronary artery disease, acute illness (unrelated to VT or its origin) or active systemic infection.
23. Subject with left ventricular assist device planned or required for the procedure
24. Females who are or may potentially be pregnant (must be post-menopausal or have a negative pregnancy test)
25. Allergy or contraindications to the medications/agents used during a standard ablation/EP intervention including heparin and ionic contrast media
26. Contraindication to cardiac CT
27. Subject concurrently enrolled in any other investigational drug or device study that the investigator deems would interfere with study results
28. Subject with a condition (including a chronic illness) or circumstance that the investigator feels puts the subject at an unacceptable risk for participation in the study or may interfere with quality data collection or study results
29. Subject is not willing or is unable to participate in all study procedures and follow-up requirements
\-
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Thermedical, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael Curley, PhD
Role: STUDY_DIRECTOR
Thermedical, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham
Birmingham, Alabama, United States
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Intermountain Healthcare
Salt Lake City, Utah, United States
Montreal Heart Institute - Institut de Cardiologie de Montréal
Montreal, Quebec, Canada
Quebec Heart and Lung Institute - Institut universitaire de cardiologie et de pneumologie de Québec
Québec, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Mary Gnap
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CP-90001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.